SHREYASKUMAR PATEL to Dose-Response Relationship, Drug
This is a "connection" page, showing publications SHREYASKUMAR PATEL has written about Dose-Response Relationship, Drug.
Connection Strength
0.372
-
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 11; 18(11):1493-1501.
Score: 0.082
-
Long-term efficacy of imatinib for treatment of metastatic GIST. Cancer Chemother Pharmacol. 2013 Aug; 72(2):277-86.
Score: 0.060
-
Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance. Cancer Treat Rev. 2012 Aug; 38(5):467-72.
Score: 0.055
-
Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008 Mar; 44(4):501-9.
Score: 0.042
-
Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors. Curr Oncol Rep. 2003 Jul; 5(4):273.
Score: 0.031
-
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9.
Score: 0.027
-
Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.
Score: 0.021
-
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. J Clin Oncol. 1997 Jun; 15(6):2378-84.
Score: 0.020
-
Standard and high dose chemotherapy for advanced soft tissue sarcomas. Ann Oncol. 1992 Apr; 3 Suppl 2:S81-3.
Score: 0.014
-
Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010 Oct 01; 16(19):4884-91.
Score: 0.013
-
A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res. 2003 Jul; 9(7):2426-34.
Score: 0.008